Article: 3D Tissue-Engineered Vascular Drug Screening Platforms: Promise and Considerations.
Frontiers in cardiovascular medicine
2022 Volume 9, Page(s) 847554
Abstract: Despite the efforts devoted to drug discovery and development, the number of new drug approvals have been decreasing. Specifically, cardiovascular developments have been showing amongst the lowest levels of approvals. In addition, concerns over the ... ...
| Abstract | Despite the efforts devoted to drug discovery and development, the number of new drug approvals have been decreasing. Specifically, cardiovascular developments have been showing amongst the lowest levels of approvals. In addition, concerns over the adverse effects of drugs to the cardiovascular system have been increasing and resulting in failure at the preclinical level as well as withdrawal of drugs post-marketing. Besides factors such as the increased cost of clinical trials and increases in the requirements and the complexity of the regulatory processes, there is also a gap between the currently existing pre-clinical screening methods and the clinical studies in humans. This gap is mainly caused by the lack of complexity in the currently used 2D cell culture-based screening systems, which do not accurately reflect human physiological conditions. Cell-based drug screening is widely accepted and extensively used and can provide an initial indication of the drugs' therapeutic efficacy and potential cytotoxicity. However, |
|---|---|
| Language | English |
| Publishing date | 2022-03-04 |
| Publishing country | Switzerland |
| Document type | Journal Article ; Review |
| ZDB-ID | 2781496-8 |
| ISSN | 2297-055X |
| ISSN | 2297-055X |
| DOI | 10.3389/fcvm.2022.847554 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.